BeautyHealth reported a 14% increase in net sales to $86.3 million, driven by strong consumer demand for Hydrafacial treatments. The company raised its fiscal year 2023 net sales guidance to $460 - $480 million and reaffirmed its adjusted EBITDA margin guidance of 18% - 20%.
Net sales increased by 14% year-over-year, reaching $86.3 million.
Consumables net sales grew by 21% year-over-year globally, with significant growth in the Americas (+34%) and EMEA (+13%).
Delivery system sales increased by 9% year-over-year.
The company raised its fiscal year 2023 net sales guidance to $460 - $480 million.
The company raised its fiscal year 2023 net sales guidance to a range of $460 to $480 million due to continued strength in consumer demand, strong Syndeo traction globally, and a re-acceleration in China. The adjusted EBITDA margin is expected to be 18%-20%.
Visualization of income flow from segment revenue to net income